Ashbeck Erin L, Rosenberg Robert D, Stauber Patricia M, Key Charles R
Epidemiology and Cancer Prevention, Cancer Research and Treatment Center, University of New Mexico Health Sciences Center, New Mexico, USA.
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):467-72. doi: 10.1158/1055-9965.EPI-06-0394. Epub 2007 Mar 2.
We examine benign breast biopsy diagnoses as reported by community pathologists in New Mexico and investigate associations with future breast cancer development.
Using data collected between 1992 and 2000 by the New Mexico Mammography Project and cancer data through 2003 from the New Mexico Tumor Registry, we calculated breast cancer rates following 14,602 benign breast biopsies for women ages 30 to 89 years. For comparison, we also calculated the breast cancer rate following 215,283 normal screening mammograms. Hazard ratios (HR) are presented.
We identified 480 subsequent breast cancer diagnoses among 14,602 women with benign breast biopsies and 4,402 breast cancer diagnoses among 215,283 women with mammograms assigned a "negative" or "benign finding" assessment. Histologic diagnoses in absence of atypia had an age-adjusted HR of 1.95 [95% confidence interval (95% CI), 1.77-2.15]. Among low-risk histologic diagnoses, the strongest associations with subsequent breast cancer development included adenosis, apocrine metaplasia, calcifications, and ductal hyperplasia. Fibroadenoma, inflammation, and cysts did not exhibit an association with breast cancer development. Women with low-risk diagnoses and breast tissue characterized as fatty or with scattered densities had a HR of 2.09 (95% CI, 1.68-2.60), whereas women with low-risk histologic diagnoses and dense breasts had a HR of 3.36 (95% CI, 2.83-3.99).
The observed breast cancer occurrence contributes to evidence of increased risk following benign biopsy. The risk associated with histologic diagnoses in absence of atypia was twice the risk experienced by women with normal mammogram evaluations and may be modified by breast density.
我们研究了新墨西哥州社区病理学家报告的良性乳腺活检诊断结果,并调查了其与未来乳腺癌发生之间的关联。
利用新墨西哥州乳腺摄影项目在1992年至2000年期间收集的数据以及新墨西哥肿瘤登记处截至2003年的癌症数据,我们计算了14602名年龄在30至89岁的女性进行良性乳腺活检后的乳腺癌发病率。作为对比,我们还计算了215283名乳腺钼靶筛查结果为“阴性”或“良性发现”的女性的乳腺癌发病率。给出了风险比(HR)。
在14602名进行良性乳腺活检的女性中,我们确定了480例后续乳腺癌诊断;在215283名乳腺钼靶检查结果为“阴性”或“良性发现”的女性中,有4402例乳腺癌诊断。无异型性的组织学诊断的年龄调整后风险比为1.95[95%置信区间(95%CI),1.77 - 2.15]。在低风险组织学诊断中,与后续乳腺癌发生关联最强的包括腺病、大汗腺化生、钙化和导管增生。纤维腺瘤、炎症和囊肿与乳腺癌发生无关联。低风险诊断且乳腺组织为脂肪型或散在致密型的女性风险比为2.09(95%CI,1.68 - 2.60),而低风险组织学诊断且乳腺致密的女性风险比为3.36(95%CI,2.83 - 3.99)。
观察到的乳腺癌发生情况为良性活检后风险增加提供了证据。无异型性的组织学诊断相关风险是乳腺钼靶检查正常女性所经历风险的两倍,且可能受乳腺密度影响。